We provide a family of ordinary and delay differential equations to model the dynamics of tumorgrowth and immunotherapy interactions. We explore the effects of adoptive cellular immunotherapy on the model and describe under what circumstances the tumor can be eliminated. The possibility of clearing the tumor, with a strategy, is based on two parameters in the model: the rate of influx of the effector cells and the rate of influx of IL-2. The critical tumor-growth rate, below which endemic tumor does not exist, has been found. One can use the model to make predictions about tumor dormancy.
Introduction
Cancer is one of the most difficult diseases to be treated clinically, and one of the main causes of death. It is the second fatal disease after the cardiovascular diseases. The World Health Organization estimates that the annual cancer-induced mortality number exceeds six million people. Accordingly, the fight against cancer is of major public health interest. For this and other economy-related reasons, a great research effort is being devoted to understand the dynamics of cancer and to predict the impact of any changes on the system reactors. Hence, mathematical models are required to help design therapeutic strategies.
In cancer modeling, we have to care about the scaling problem, where the class of equations, used to describe the model, are to be determined. Indeed, there are three natural scales, which are connected to the different stages of the disease and have to be identified. The first is the subcellular or molecular scale, where we focus on studying the alterations in the genetic expressions of the genes contained in the nucleus of a cell, as a result of some Immunotherapy models and their predictions have been extensively studied in 9, 14, 19 . In 14 , Kirschner et al. explored the role of cytokine in the disease dynamics and studied the long-term tumor recurrence and short-term tumor oscillations. However, in 19 Kuznetsov and Knott presented a mathematical model for the growth and suppression of the tumor. They showed that the model can describe the regrowth of a dormant tumor by two distinct mechanisms. One explanation for the tumor regrowth is based on a single clone model, while the other is based on a two-clone model. They fitted their ODE models to the data and obtained several curves for the tumor regrowth. They compared their predicted results with clinical and experimental observations, where both results confirm that intensive limited-term immunotherapy does not provide complete tumor elimination. The simulations show that medium-term control of cancer is exhibited when long-life immune memory cells are activated, but long-term control results from reducing the cancer growth rate.
In this paper, we investigate mathematical models for the dynamics between tumor cells, immune-effector cells, and the cytokine interleukin-2 IL-2 . It is worth stressing that we operate at a supermacroscopic scale, namely, by ordinary differential equations. However, the link to lower cellular scale is represented by the delay. The delay differential equations have long been used in modeling cancer phenomena 20-26 . It should be noted that the heterogeneity, mutations, and link with the lower molecular scale are neglected. These topics are documented in 17, 27, 28 .
The organization of this paper is as follows: in Section 2, we provide different models, using ODEs and DDEs, with interaction functions in the Lotka-Volterra form to describe the response of the effector cells to the growth of tumor cells. In Section 3, we study the local stability of the steady states for tumor-free and endemic persistence. Bifurcation analysis for a three-equations model and finding regions of existence of the equilibria are discussed in Section 4. In Section 5, we discuss the conditions that ensure tumor-clearance possibilities and conclude in Section 6.
The Model
The model of Kuznetsov et al. 7 describes the response of the effector cells ECs to the growth of tumor cells TCs . In this model, it has been taken into account the penetration of TCs by ECs, which simultaneously causes the inactivation of ECs. It is assumed that interactions between ECs and TCs are in vitro such that E, T , C, E * , and T * denote the local concentrations of ECs, TCs, EC-TC conjugates, inactivated effector cells, and "lethally hit" TCs, respectively. The rate of binding of ECs to TCs and the rate of separation of ECs from TCs without damaging them are denoted by k 1 and k −1 , respectively. The rate at which EC-TC integrations program for lysis is denoted by k 2 , while the rate at which EC-TC interaction inactivate ECs is denoted by k 3 . The model takes the form
2.1
Here, the parameter s represents the normal rate not increased by the presence of the tumor of the flow of adult ECs into the tumor site and F C, T describes the accumulation of ECs in the tumor site, while d 1 , d 2 , and d 3 are the coefficients of the processes of destruction and migration of E, E * , and T * , respectively. The maximal growth of tumor is represented by the coefficient a, and b is the environment capacity. It was suggested in 7 that the function F takes the form
where p and r are positive constants. This term is the Michaelis-Menten form to indicate the saturated effects of the immune response. The idea in this paper is to simplify the above model and reduce it into a two-or threeequation model to describe the interactions of three types of cell populations: the activated immune-system cells, E t or effector cells such as cytotoxic T-cells, macrophages, and natural killer cells that are cytotoxic to the tumor cells ; the tumor cells, T t ; the concentration of IL-2 in the single tumor-site compartment, I L t . The above model can then be governed by the following three equations see 14 :
where c is the antigenicity rate of the tumor, s 1 is the external source of the effector cells, with rate of death μ 1 , whereas the parameter r 2 incorporates both multiplication and death of tumor cells. The maximal carrying capacity of the biological environment for tumor cell is b −1 , θ 1 is considered as the cooperation rate of effector cells with Interleukin-2 parameter, α is the rate of tumor cells, and θ 2 is the competition rate between the effector cells and the tumor cells. External input of IL-2 into the system is s 2 , and the rate loss parameter of effector cells is μ 2 .
Nondimensionalization
System 2.3 is an example of stiff One definition of the stiffness is that the global accuracy of the numerical solution is determined by stability rather than local error and implicit methods are more appropriate for it. model, in the sense that it has properties that make it slow and expensive to solve using explicit numerical methods. Stiffness often appear due Journal of Applied Mathematics 5 to the differences in speed between the fastest and slowest components of the solutions, and stability constraints. The efficient use of reliable numerical methods, that is based in general on implicit formulae, for dealing with stiff problems involves a degree of sophistication not necessarily available to nonspecialists 29 . In addition, the state variables of these types of models are very sensitive to small perturbations or changes in the parameters occuring in the model. Consequently, the parameter estimates are also sensitive to the noisy data and observations. To ease the analysis and stability of the steady states with meaningful parameters and less sensitive or rubus model, we nondimensionalize the bilinear model 2.3 , by taking the following rescaling:
2.4
Therefore, after the above substitution into 2.3 and replacing τ by t, the model becomes
2.5
with initial conditions x 0 x 0 , y 0 y 0 , and z 0 z 0 . Here x t , y t , and z t denote the dimensionless density of ECs, TCs, and LI-2, respectively. In model 2.5 , there are four possible cases of treatments, according the values of s 1 and s 2 : i notreatment case s 1 s 2 0 , ii adoptive cellular immunotherapy case s 1 > 0, s 2 0 , iii interleukin-2 case s 1 0, s 2 > 0 , iv and immunotherapy with both adoptive cellular immunotherapy ACI and IL-2 s 1 > 0, s 2 > 0 . Yafia 10 considered system 2.5 in the absence of immunotherapy with IL-2,
where ω is immune response to the appearance of the TCs, s has the same meaning of s 1 , r has the meaning of r 2 , and μ has the meaning of μ 1 in the above model. If we consider a time 6 Journal of Applied Mathematics delay τ > 0 in 2.6 due to the time-lag in the interaction between ECs and TCs, the model takes the form
2.7
In this model, we only consider the time delay in the dependent variable y representing tumor of the nonlinear term. Of course other models assume time delays in both variables x and y 6 . Further models that consider time delays when modeling tumor growth are discussed in 30-32 . To solve model 2.7 , we should provide an initial function with initial function y t ψ t , t ∈ −τ, 0 instead of the initial value y 0 at t 0 see 3 . It has been shown that model 2.7 has visible and bounded solution see 6, 11 . When the time delay is included in the simplified model 2.6 , the state of returning tumor cells can be observed, as DDE models have richer dynamics than do ODE models; see the graphs displayed in Figures 1, 2 , and 3. We next study the stability of the steady states of the above models, according the values of the parameters given in Table 1 . 
Steady States and Stability
The solutions of practical interest should have nonnegative population x, y, and z. However, it is hard to find a closed analytical solution for the above nonlinear models, instated we can study their qualitative behavior by studying the stability of the steady states. We then assume that the parameters occuring in the models are also nonnegative. 
Tumor-Free Equilibrium and Its Stability
To ease the analysis, we start with the 2-population model 2. 6 Puting λ ξi in 3.2 and separating real and imaginary parts yields
3.3
Therefore, when |rμ| < |s| there are no positive real root ξ. This shows that all the roots of 3.1 have negative real parts and E 0 is asymptotically stable. In case of the three-equation model 2.5 , and at the equilibrium points, we have
Putting y 0 yields the tumor-free equilibrium, namely,
It is clear that the infection-free equilibrium E 0 exists if and only if s 2 < μ 1 μ 2 /θ 1 . Therefore, we restrict our analysis to the case where s 2 < μ 1 μ 2 /θ 1 . To study its stability, we consider the corresponding Jacobian matrix
It has the eigenvalues −μ 1 θ 1 s 2 /μ 2 , r 2 − αs 1 μ 2 / μ 1 μ 2 − θ 1 s 2 , and −μ 2 . Therefore, E 0 is locally asymptotically stable if and only if r 2 < αs 1 μ 2 / μ 1 μ 2 − θ 1 s 2 , while otherwise it is an unstable saddlepoint.
Endemic Equilibrium and Its Stability
Consider again the two-equation model 2.6 . If y / 0, the steady states are obtained by solving ωrby 2 −r ω μb y μr−s 0. In this case, we have two endemic equilibria P 1 x 1 , y 1 and P 2 x 2 , y 2 , where
2rbω ,
with Δ r 2 bμ − ω 2 4ωrbμ > 0. The Jacobian matrix of the system 2.6 at the endemic equilibrium P 1 is
Proposition 3.1. If the endemic equilibrium P 1 exists and has nonnegative coordinates, then tr J endemic > 0 and P 1 is unstable.
Proof. Since
then inequality tr J endemic > 0 is true if
Therefore, when rμ < s and ω < −bμ, we have ω 2 −ωb r μ −rμb 2 > 0 and hence both sides of the inequality are positive. Therefore, if the point P 1 exists and has nonnegative coordinates, then tr J endemic > 0 and the point P 1 is unstable whenever ω < −bμ and rμ < s.
Similarly, it is easy to prove the following proportion.
Proposition 3.2. If the point P 2 exists and has nonnegative coordinates, then it is asymptotically stable.
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We extend the above analysis to the case of the three-equation model 2.5 . The tumorpersistent solutions are obtained by putting y / 0 and omitting x and z in 3.4 to get a scalar equation in the variable y which reads
3.12
Since s 2 < μ 1 μ 2 /θ 1 , then the coefficient C 1 is always positive, while the coefficient C 0 can take positive and negative values depending on the values of the model parameters. Also, 3.11 is welldefined for all y ∈ 0, 1/b . Its left-hand side is a polynomial of degree three, and its zeros are not easy to be obtained in a closed-form. However, some conditions in the parameters occur in the model to ensure the existence of its solutions could be deduced. Equation 3.11 can also be seen as a bifurcation equation in r 2 and y, where we keep all other parameters fixed. Once a solution y > 0 of this equation has been obtained, we could find positive x and z from the other equations in 3.4 . Therefore, there is a one-to-one correspondence between the solutions of 3.11 and the endemic stationary solutions. For more insights, we next study the bifurcation analysis.
Bifurcation Analysis of Model 2.5
The bifurcation analysis gives a deeper analysis about the model. It answers the query that "how does the behavior of the solutions change as parameters change." We restrict ourselves to only study the bifurcation analysis of ODEs models rather than DDEs models.
Bifurcation Points for the Parameter r 2
In this subsection, we then analyze the bifurcation so that the tumor growth rate r 2 acts as a bifurcation parameter. Therefore, to find the bifurcation point s , we put y 0 in 3.11 to get r 2 αμ 2 s 1 / μ 1 μ 2 − θ 1 s 2 : r 2 . Hence, there is only one transcritical bifurcation point at
Now, we compute the direction of bifurcation at r 2 , 0 so that
Hence, the bifurcation at the point r 2 , 0 is forward, irrespective of the values of the modelparameters. We notice that the model we consider here has only one bifurcation point r 2 , 0 at which the bifurcation is forward.
Bifurcation Diagrams for the Parameter ∝
The parameter α is very important in the model that plays an effective role to define cancer behavior. We investigate numerically, in this subsection, the bifurcation of the model for the parameter α. We consider the four cases: no treatment case s 1 s 2 0 , adoptive cellular immunotherapy case s 1 > 0, s 2 0 , interleukin-2 case s 1 0, s 2 > 0 , and immunotherapy with both ACI and IL-2 case s 1 > 0, s 2 > 0 . If we solve F y, α F α, y 0 in α, we have
4.4
To plot α, y in the interval 0 < y < 1/b, under the conditions that
we have
For 0 < y < y , where
we have two cases y < 1/b or y > 1/b. The graphs in Figure 4 , which are obtained numerically, display the bifurcation diagrams for different cases, where i s 1 s 2 0, ii s 1 10, s 2 0, iii s 1 0, s 2 40, and vi s 1 10, s 2 40. Given the threshold point α, y α * , 0 , the tumor clearance condition is α > α * , where
Therefore, when s 1 > 0, then α * > 0 and α ∝ 1/s 1 . Thus, we can arrive to tumor clearance quickly when the value of s 1 increases. We notice from Figure 4 that the locations of saddle node bifurcation points A and B bridge the one-positive equilibrium to the three-positive equilibria. The supercritical Hopf bifurcation point C joints between existence of stable limit cycles and nonexistence of limit cycles. The transcritical bifurcation point D at α, y α * , 0 bridges the one-positive equilibrium and no positive equilibria.
Regions of Existence of the Equilibria
In addition to the tumor-free equilibrium, 3.11 may have one to three persistent-tumor equilibria, depending on the values of the model-parameters. However, before we proceed we provide the following proposition, which is helpful in the analysis. Proof. Since the bifurcation direction at the point r 2 , 0 is always forward, then 3.11 has two positive roots, for r 2 < r 2 , if and only if F r 2 , y y c 3 y 2 C 2 y C 1 0 has two positive zeros, where
4.10
However, C 2 2 − 4C 1 C 3 −4C 3 μ 2 α 2 bs 1 cμ 2 < 0. Therefore, the proof is complete. Now, to find the conditions, on the model parameters, being required for the existence of the persistent equilibria, we make the use of both Descant's rule of signs and the Sturm sequence 33 . In 3.11 , it is clear that the coefficients C 3 , C 2 , and C 1 have fixed signs, while the coefficient C 0 can take positive or negative values. Hence, the number of feasible tumor-persistent equilibria on the interval y ∈ 0, 1/b depends on the difference Figure 4 : shows the bifurcation diagrams for the bilinear model 2.5 for the parameter α: -represents the stable equilibrium, ---represents the unstable equilibrium, · · · is the stable limit cycles, while • is the saddle node bifurcation. • is the transcritical bifurcation and the supercritical Hopf bifurcation. The values of parameters are given in Table 1 . Table 2 : The number of positive steady states SS is determined by the signs of the coefficients 3.11 and the signs of the quantities R, S, and T from the Sturm sequence. Blank entries correspond to coefficients which may take positive, negative, or zero values.
between the number of sign changes at y 0 and at y 1/b in the Sturm sequence {P 0 y , P 1 y , P 2 y , P 3 y }, such that
4.11
Hence the number of sign changes depends on the sign of the coefficient C 0 and the remainders R, S, and T . Table 2 shows the conditions required for the existence of persistent-tumor equilibria as well as their numbers, where we take into account that C 0 > 0 implies S < 0. We may note that the tumor-persistent equilibria do not exist for C 0 > 0, while one or three equilibria exist depending on the other relevant quantities. The interest is to find the area where the tumor-free equilibrium is a global attractor. Based on Proposition 4.1 and Table 2 , this area is determined by C 0 > 0 that is equivalent to
where r 2 is the critical growth rate of the tumor cell population, separating between nonexistence and existence of positive endemic equilibria. If we consider the general case of immunotherapy with both ACI and IL-2 treatments, then according to the conditions given in Table 2 and data displayed in Figure 4 , then Figure 5 displays six stability regions in terms of the two parameters α, r 2 according to the number of positive equilibria and the limit cycles . However, Figure 6 shows phase spaces for different equilibria where there are stable steady states, unstable steady states, stable manifold, unstable manifold and initial conditions. For example, Figure 6 f shows the trajectories where there are three tumor-persistent equilibria for which two of them are locally stable and one, lying in between, for tumor-free equilibrium, is unstable that correspond to region 3.b in Figure 5 . Figure 6 e shows the trajectories where there are three tumor-persistent equilibria for which one of them is locally stable, one is stable limit cycles, and one, lying in between, for tumor-free equilibrium is unstable that correspond to region 3.a in Figure 5 .
Tumor-Clearance Possibilities
Let us introduce the following definition to facilitate the analysis. Figure 5 : The two-dimensional transition structure as a function of α the tumor cell is predated by effector cells rate and r 2 the maximal growth rate of the tumor cells population : sd is the saddle node bifurcation, ts is the transcritical bifurcation, and hf is the supercritical Hopf bifurcation. Immunotherapy with both ACI and IL-2 Case; see Table 1 and s 1 40, s 2 10. .
Definition 5.1. The threshold parameter R 0 the minimum tumor-clearance parameter is the parameter that has the property that if R 0 < 1, then the endemic tumor does not exist, while if R 0 > 1 the tumor persists see 34 .
The parameter R 0 can then be expressed in terms of the ratio between the tumorgrowth rate and the critical tumor-growth rate separating between nonexistence and existence of endemic tumor. Now, for the three-equations model, the tumor-free equilibrium is the unique equilibrium if and only if r 2 < r 2 , where it is also locally asymptotically stable. Therefore, the minimum tumor-clearance parameter is R 0 r 2 /r 2 and clearing the tumor requires the achievement of the inequality R 0 < 1. It is equivalent to the following set of inequalities:
Hence clearing the tumor depends mainly on the concentration of treatments: the external source of effector cells s 1 and the treatment s 2 , which represents the external input of IL-2. If s 2 0, then the tumor can be cleared by treatment with adoptive cellular immunotherapy alone, s 1 > μ 1 /α r 2 . However, for s 1 0, then the inequality r 2 < r 2 cannot be held and therefore, it is impossible to treat cancer by IL-2 alone. However, a strategy based on using both adoptive immunotherapy and IL-2 with concentrations s 2 < s 2 and s 1 > s 1 could be used to clear the tumor; see Figure 7 . We arrive to the following corollary.
Corollary 5.2. In the tumor-clearance problem, we have the following three cases:
i if s 1 0, the tumor could never be cleared, , stable manifold ---, unstable manifold · · · , and initial conditions , exist. with immunotherapy with both ACI and IL-2, see Table 1 and s 1 40, s 2 10. . Tumor-free region Tumor-endemicity region s 2 = 1.5 * 10 8 Figure 7 : The critical s 1 as a function of r 2 for several levels of s 2 . For values of s 1 above the threshold s 1 , the tumor cells do not exist with α 0.5556 , see Table 1 .
ii if s 2 0, the tumor could be cleared by adding an external source of effector cells with concentration slightly above s 1 μ 1 /α r 2 ,
iii if s 1 / 0 and s 2 / 0, then the tumor could be cleared with concentrations s 2 < μ 1 μ 2 /θ 1 and s 1 > μ 1 μ 2 − θ 1 s 2 /μ 2 α r 2 .
Summary and Conclusion
In this paper, we introduced a family of differential models ODEs and DDEs to describe the dynamics of cancer. The ODEs models model cancer at supermacroscopic, in the sense that they describe the interaction between the tumor cells and the normal immune cells 1 . However, the DDEs models link it with the lower cellular scale. The qualitative and evolution of the models have been displayed with different values of the parameters α the rate of tumor cells predated by the effector cells and r 2 the maximal growth rate of the tumor cells population . Although the underlying models are simple, they display very rich dynamics and give a good picture for the phenomena of real interaction of tumor growth and immunotherapy. The minimum tumor-clearance parameter R 0 has been expressed in terms of the ratio between the tumor-growth rate and the critical tumor-growth rate. The cases at which the tumor can be cleared are summarized in Corollary 5.2. The obtained results can help to gain a better understanding of interaction mechanisms and make predictions, determine and evaluate control strategies, and convey more general insight to biologists. The numerical simulations have been obtained by semi-implicit RK methods 29 demonstrate that the system with time delay exhibits richer complex dynamics, such as quasiperiodic and chaotic patterns, compared with models without memory or after-effect. The steady states of DDEs models are similar to the steady states of ODEs models. We shall extend this work to investigate the qualitative behavior and bifurcation analysis of more sophisticated models of DDEs in modeling tumor-immune interactions with immunotherapy and control functionals to maximize the effector cells and interleukin-2 concentration and to minimize the tumor cells.
